Hasil Pencarian - Yulia Jitkova

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity.

    A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. oleh Yulia Jitkova, Marcela Gronda, Rose Hurren, Xiaoming Wang, Carolyn A Goard, Bozhena Jhas, Aaron D Schimmer

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells.

    Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. oleh Bozhena Jhas, Shrivani Sriskanthadevan, Marko Skrtic, Mahadeo A Sukhai, Veronique Voisin, Yulia Jitkova, Marcela Gronda, Rose Hurren, Rob C Laister, Gary D Bader, Mark D Minden, Aaron D Schimmer

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia

    The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute my... oleh Dana Yehudai, Sanduni U. Liyanage, Rose Hurren, Biljana Rizoska, Mark Albertella, Marcela Gronda, Danny V Jeyaraju, Xiaoming Wang, Samir H. Barghout, Neil MacLean, Thirushi P. Siriwardena, Yulia Jitkova, Paul Targett-Adams, Aaron D. Schimmer

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

    A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia oleh Gregory A. Reed, Gary J. Schiller, Suman Kambhampati, Martin S. Tallman, Dan Douer, Mark D. Minden, Karen W. Yee, Vikas Gupta, Joseph Brandwein, Yulia Jitkova, Marcela Gronda, Rose Hurren, Aisha Shamas‐Din, Andre C. Schuh, Aaron D. Schimmer

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A porphodimethene chemical inhibitor of uroporphyrinogen decarboxylase.

    A porphodimethene chemical inhibitor of uroporphyrinogen decarboxylase. oleh Kenneth W Yip, Zhan Zhang, Noriko Sakemura-Nakatsugawa, Jui-Wen Huang, Nhu Mai Vu, Yi-Kun Chiang, Chih-Lung Lin, Jennifer Y Y Kwan, Shijun Yue, Yulia Jitkova, Terence To, Payam Zahedi, Emil F Pai, Aaron D Schimmer, Jonathan F Lovell, Jonathan L Sessler, Fei-Fei Liu

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

    Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia oleh Qi Zhang, Bridget Riley-Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej N. Konoplev, Shannon R. Sweeney, Jeremy A. Ryan, Yulia Jitkova, Kenneth Dunner, Shaun E. Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen Kurtz, Vivian R. Ruvolo, Helen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, Richard Eric Davis, Venkata L. Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso-Ramos, Stefano Tiziani, Joel Leverson, Relja Popovic, Marina Konopleva

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

    Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia oleh Qi Zhang, Bridget Riley-Gillis, Lina Han, Yanan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej N. Konoplev, Shannon R. Sweeney, Jeremy A. Ryan, Yulia Jitkova, Kenneth Dunner, Shaun E. Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen Kurtz, Vivian R. Ruvolo, Helen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, Richard Eric Davis, Venkata L. Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso-Ramos, Stefano Tiziani, Joel Leverson, Relja Popovic, Marina Konopleva

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: